About Visiopharm
Visiopharm is a leading provider of AI-driven precision pathology software serving both research and diagnostic markets. Founded in 2002, the company combines 20 years of pathology expertise with advanced artificial intelligence to deliver accurate and versatile tissue analysis solutions. In research, Visiopharm provides technology leadership through tools that help scientists, pathologists, and image analysis experts produce accurate data for all types of tissue-based research. Their flagship products include Discovery for tissue image analysis and Phenoplex for spatial biology, both featuring deep learning capabilities and customizable workflows. In diagnostics, Visiopharm leads in clinical applications with nine diagnostic algorithms cleared under IVDR for EU customers, providing diagnostic decision support that integrates seamlessly into existing laboratory workflows through PACS/IMS systems like Sectra IDS7 and Proscia Concentric AP. The company also offers Qualitopix for IHC staining consistency measurement and quality control. Visiopharm serves over 750 customer accounts across more than 40 countries, supporting applications in oncology, neurology, hepatology, nephrology, dermatology, and other therapeutic areas. Their software enables researchers and pathologists to build tailored analysis workflows for drug discovery, spatial biology, clinical research, and laboratory-developed tests (LDTs). The company is privately owned and operates internationally with headquarters in Denmark's Medicon Valley and legal entities in Sweden, the UK, Germany, the Netherlands, and the United States, plus local representation in France and China.
Mission & Story
Mission
Built to help you stay ahead. Our unique software combines 20 years of knowledge gained by working with pathologists and research scientists with the power of AI. We provide you with the accuracy and versatility you need to meet the tissue analysis challenges of tomorrow in research and diagnostics.
Clinical Focus
Medical conditions and clinical areas addressed by Visiopharm.
Who It Serves
Milestones & Awards
Recent Milestones
Phenoplex v3 launched April 2024 with advanced spatial neighborhood capabilities. Multiple software updates in 2025-2026. Visiopharm Tech Talks launched June 2026. New feature to overcome local and cloud IT performance issues released April 2026.
Key Partnerships
Social & Media
Latest Updates
Company Details
- Founded
- 2002
- Headquarters
- Medicon Valley, Denmark
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 45 →
Aiforia
Aiforia provides AI-powered digital pathology solutions for clinical diagnostics and research. The company offers cloud-based deep learning tools and CE-IVD marked clinical suites for analyzing pathology images across multiple cancer types, serving pathologists, researchers, and diagnostic laboratories worldwide.
Aignostics
Aignostics develops AI-powered pathology solutions for precision medicine, specializing in tumor microenvironment analysis from H&E-stained whole slide images. The company serves life sciences companies and academic researchers with foundation models and custom analytics services.
Aiosyn
Aiosyn develops AI-powered computational pathology software that integrates into standard digital pathology workflows. The company specializes in deep learning solutions for cancer and chronic kidney disease diagnostics, serving clinical laboratories, biopharma, and CROs.
AIxMed
AIxMed develops AI-powered computational cytology platforms for cancer detection and diagnosis. The company's flagship product AIxURO analyzes urine cytology for bladder cancer, with additional platforms in development for thyroid, cervical, and lung cancer screening.
Akoya Biosciences
Akoya Biosciences, now part of Quanterix, provides spatial biology solutions for high-plex tissue analysis. The company develops instruments, assays, and software for spatial proteomics research, enabling researchers to map biomarkers at single-cell resolution in tissue samples.
Caris Life Sciences
Caris Life Sciences is a leading precision medicine company that provides comprehensive molecular profiling for cancer patients. The company combines genomic, transcriptomic, and proteomic data with AI to deliver personalized treatment insights for oncologists and patients.
CellaVision
201-500 employees
CellaVision is a world-leading provider of digital hematology microscopy solutions covering analyzers, instruments, reagents, and software. The company automates workflows in hematology laboratories of all sizes for human and animal blood and body fluid sample analysis.
Clever Culture Systems
Clever Culture Systems develops AI-powered automated microbiology culture plate reading technology for pharmaceutical and clinical laboratories. Their flagship product, APAS Independence, automates the imaging, interpretation, and reporting of microbial growth on culture plates.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.